)
Visual
test
ProQR Therapeutics
ProQR Therapeutics (PRQR) investor relations material
ProQR Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Advanced AX-0810 for cholestatic diseases into Phase 1, with target engagement data expected in 1H 2026.
Selected AX-2402 for Rett syndrome and AX-2911 for MASH as development candidates, both showing strong preclinical results.
Achieved $4.5 million in milestones from Eli Lilly collaboration in 2025.
Ended 2025 with €92.4 million in cash and cash equivalents, supporting operations into mid-2027.
Financial highlights
Cash and cash equivalents at year-end 2025 were €92.4 million, down from €149.4 million at year-end 2024.
Net cash used in operating activities was €52.8 million in 2025, compared to €36.4 million in 2024.
R&D costs rose to €44.7 million in 2025 from €36.4 million in 2024.
General and administrative costs increased to €15.1 million from €13.7 million year-over-year.
Net loss for 2025 was €42.2 million (€0.40 per diluted share), compared to €27.8 million (€0.32 per diluted share) in 2024.
Outlook and guidance
AX-0810 Phase 1 target engagement data in healthy volunteers expected in 1H 2026.
PSC patient cohort to be initiated in AX-0810 Phase 1 after healthy volunteer cohorts.
AX-2402 for Rett syndrome to enter first-in-human study in 1H 2027.
Continued execution on Lilly collaboration with potential for further milestone payments and data updates in 2026.
Criteria for AX-0810 PSC cohort initiation
Lilly collaboration data update expectations
AX-2402 functional improvement data details
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ProQR Therapeutics
- Lead RNA editing program in phase I, with major data and milestones expected in 2024.PRQR
The Citizens Life Sciences Conference 202611 Mar 2026 - Axiomer RNA editing platform nears clinical entry, with key data and partnership milestones ahead.PRQR2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- Pipeline advances and strong financials position the company for multiple clinical milestones.PRQRAGM 202411 Jan 2026
- Up to $300M in securities offered to fund RNA therapy pipeline, with significant investor risks.PRQRRegistration Filing16 Dec 2025
- Registration allows a major partner to resell shares as the company advances RNA editing therapies.PRQRRegistration Filing16 Dec 2025
- RNA editing pipeline advances with phase 1 data for cholestatic disease expected soon.PRQREvercore ISI 8th Annual HealthCONx Conference7 Dec 2025
- RNA editing platform advances to clinic with strong pipeline, partnerships, and cash runway.PRQRThe Citizens JMP Life Sciences Conference 202524 Nov 2025
- Initiated AX-0810 Phase 1 trial; cash runway into mid-2027 despite increased net loss.PRQRQ3 202520 Nov 2025
- AX-0810 enters phase I trials to address cholestatic diseases via NTCP RNA editing.PRQRStudy Update13 Nov 2025
Next ProQR Therapeutics earnings date
Status update8 Apr, 2026
ProQR Therapeutics
Next ProQR Therapeutics earnings date
Status update8 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage